Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Blood glucose criteria must be met~* Previously treated with a sulfonylurea for at least 3 months~* Body mass index (BMI) in the range 22-45~Exclusion Criteria:~* Type 1 diabetes~* Pregnancy or lactation~* Evidence of serious cardiovascular complications~* Evidence of serious diabetic complications~* Laboratory value abnormalities as defined by the protocol~* Known sensitivity to glimepiride~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- LAF237 50 mg qd + glimepiride 4 mg qd (Type: EXPERIMENTAL): LAF237 50 mg qd + glimepiride 4 mg qd
- LAF237 50 mg bid + glimepiride 4 mg qd (Type: EXPERIMENTAL): LAF237 50 mg bid + glimepiride 4 mg qd
- LAF237 placebo + glimepiride 4 mg qd (Type: PLACEBO_COMPARATOR): LAF237 placebo + glimepiride 4 mg qd

Based on this trial design, predict the completion outcome and termination type (if applicable).